Monte Rosa Therapeutics, Inc. Cash Flow Statement
GLUE / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Monte Rosa Therapeutics, Inc. generated $42M in operating cash flow and $38M in free cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Net Income | -$72.7M | -$135.4M | -$108.5M | -$74.0M | -$35.9M |
| Depreciation & Amortization | $8.1M | $6.2M | $3.7M | $2.1M | $537.0K |
| Operating Cash Flow | $42.0M | -$43.8M | -$92.5M | -$59.4M | -$23.1M |
| Capital Expenditures | $4.0M | $19.0M | $12.9M | $9.7M | $3.4M |
| Free Cash Flow | $38.0M | -$62.8M | -$105.4M | -$69.1M | -$26.4M |
| Dividends Paid | $0 | $0 | $0 | $0 | - |